Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 11, 2018
Event: Entry into a Material Definitive Agreement (Second Amendment to Equity Purchase Agreement) regarding the sale of the DaVita Medical Group (DMG) division to Collaborative Care Holdings, LLC (a subsidiary of Optum, Inc.).
Key Financial Metrics and Transaction Terms
- Revised Purchase Price: Reduced from $4,900,000,000 to $4,340,000,000 (subject to adjustments).
- Expected Impairment Charge: Approximately $200,000,000 to $250,000,000 to be recorded in the fourth quarter of 2018.
- Liability Thresholds: The "Threshold" for claims reduced from $73,500,000 to $65,100,000.
- Aggregate Liability Cap: DaVita's aggregate liability for specific claims reduced from $367,500,000 to $325,500,000.
- Regulatory Status: California Department of Managed Health Care approval received; Federal Trade Commission (FTC) approval remains the final condition.
Material Changes Versus Prior Period
The filing details a material amendment to the Equity Purchase Agreement originally dated December 5, 2017, and previously amended in September 2018. Key changes include:
- Price Reduction: A decrease of $560,000,000 in the agreed purchase price attributed to underlying business performance.
- Measurement Date Adjustment: The measurement date for a "Seller Material Adverse Effect" regarding financial condition has been reset from December 5, 2017, to the date of the Second Amendment (December 11, 2018).
- Impairment Recognition: The price reduction necessitates a significant non-cash charge in Q4 2018, which was not present in prior periods.
Guidance, Outlook, and Risks
Outlook and Timing: The parties expect to close the transaction in the first quarter of 2019, pending FTC approval. DaVita will continue to assess the carrying value of held-for-sale assets until closing.
Risks and Contingencies:
- Regulatory Risk: Uncertainty regarding the timing and receipt of FTC approval.
- Operational Disruption: Potential difficulty in maintaining business relationships during the pending transaction.
- Liquidity and Financing: Uncertainties related to liquidity post-closing and the ability to secure external financing on anticipated terms.
- Additional Impairments: Risk of recognizing further valuation adjustments or goodwill impairments related to DMG.
Investor Verification Checklist
- Verify the final status of the Federal Trade Commission (FTC) approval required to close the transaction.
- Confirm the exact amount of the impairment charge recorded in the Q4 2018 financial statements (expected range: $200M-$250M).
- Monitor DaVita's liquidity position and any announcements regarding new external financing arrangements post-closing.
- Review the "Second Amendment to Equity Purchase Agreement" (Exhibit 10.1) for specific adjustment mechanisms affecting the final purchase price.